Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lp(a)FRONTIERS CAVS trial of pelacarsen in calcific aortic valve stenosis
2022-502135-19-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in calcific aortic stenosis (AS) comparing Pelacarsen with Placebo (2 arms). Primary endpoints: Change in peak aortic jet velocity and Change in aortic valve calcium score. Planned start Jul 2024; status: authorised.
02
Drugs
pelacarsen
03
Conditions
calcific aortic stenosis (AS)
Beyond the preview
Go deeper on 2022-502135-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502135-19-00.